A dna molecule encoding a variant .alpha.2b-adrenoceptor protein, and uses thereof
CA 2387962 A1 · Owner: Salonen, Riitta · Inventors: Nyyssonen, Kristiina; Lakka, Timo A.; Valkonen, Veli-Pekka
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
This invention relates to a DNA sequence comprising a nucleotide sequence encoding a variant .alpha.2B-adrenoceptor protein and to said variant .alpha.2B-adrenoceptor protein as well as a method for screening a subject to determine if said subject is a carrier of a variant gene that encodes said variant .alpha.2B-adrenoceptor. Further this invention relates to a method for treating a mammal suffering from vascular contraction of coronary arteries said method comprising the step of administering a selective .alpha.2Badrenoceptor antagonist to said mammal and to transgenic animals comprising a human DNA molecule encoding human .alpha.2B-adrenoceptor or said variant …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 20, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended October 20, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 20, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.